Cantor Fitzgerald has initiated coverage of Organogenesis (NASDAQ:ORGO) with an overweight rating, citing attractive valuation and the company’s highly differentiated technology portfolio.

Viewing the estimated $24B advanced wound care and surgical/sports medicine markets favorably, Cantor sees Organogenesis’s offerings as “differentiated and protected given their strong clinical data,” further noting that it was the only company to have an FDA PMA for both venous leg ulcers and diabetic foot ulcers.

Speaking candidly, Cantor revealed, “We estimate a return to growth in 2024 as the company works to regain customers that were ‘lost’ during the period of reimbursement confusion.”

The investment bank set a price target of $5 for the stock.